Neuralink teams up with Spain, California for Elon Musk’s new ‘bionic eye’ project
The post Neuralink teams up with Spain, California for Elon Musk’s new ‘bionic eye’ project appeared on BitcoinEthereumNews.com. Neuralink, Elon Musk’s brain chip company, has partnered with researchers in Spain and California on a new clinical trial for what’s being called a “Smart Bionic Eye.” The trial quietly appeared on ClinicalTrials.gov in late July, with sponsorship listed under the University of California at Santa Barbara, according to Bloomberg. The study is meant to explore how brain-computer interfaces can help blind patients see again using artificial intelligence. The trial hasn’t started using Neuralink patients yet. The listing says the research will involve Neuralink participants “once available,” and enrollment is currently by invitation only. The experimental tech is being designed to help users recognize faces, walk outdoors, and read; all through a digital system wired into the brain. There are no human test subjects confirmed yet, but the plan is to eventually implant the device into real people once it’s ready for that stage. Neuralink targets 2030 for launch of Blindsight vision chip The clinical study is part of a bigger roadmap that includes Blindsight, the name of Neuralink’s chip designed specifically to restore vision. Blindsight has only been tested in monkeys so far. Musk’s company is aiming to get the chip into patients by 2030, with expectations to reach $1 billion in yearly revenue by 2031, alongside other implant projects. There are two other devices in the company’s pipeline. One is called Telepathy, a brain chip that lets users control external devices with their mind. The second, named Deep, is being built to treat tremors and Parkinson’s disease. The company presented these plans to investors recently, with projections showing five large clinics opening in the coming years to support 20,000 surgeries annually by 2031. The numbers are based on a $50,000 reimbursement estimate per surgery. Musk is banking on regulatory approval for Telepathy in the U.S. by 2029, which…
The post Neuralink teams up with Spain, California for Elon Musk’s new ‘bionic eye’ project appeared on BitcoinEthereumNews.com.
Neuralink, Elon Musk’s brain chip company, has partnered with researchers in Spain and California on a new clinical trial for what’s being called a “Smart Bionic Eye.” The trial quietly appeared on ClinicalTrials.gov in late July, with sponsorship listed under the University of California at Santa Barbara, according to Bloomberg. The study is meant to explore how brain-computer interfaces can help blind patients see again using artificial intelligence. The trial hasn’t started using Neuralink patients yet. The listing says the research will involve Neuralink participants “once available,” and enrollment is currently by invitation only. The experimental tech is being designed to help users recognize faces, walk outdoors, and read; all through a digital system wired into the brain. There are no human test subjects confirmed yet, but the plan is to eventually implant the device into real people once it’s ready for that stage. Neuralink targets 2030 for launch of Blindsight vision chip The clinical study is part of a bigger roadmap that includes Blindsight, the name of Neuralink’s chip designed specifically to restore vision. Blindsight has only been tested in monkeys so far. Musk’s company is aiming to get the chip into patients by 2030, with expectations to reach $1 billion in yearly revenue by 2031, alongside other implant projects. There are two other devices in the company’s pipeline. One is called Telepathy, a brain chip that lets users control external devices with their mind. The second, named Deep, is being built to treat tremors and Parkinson’s disease. The company presented these plans to investors recently, with projections showing five large clinics opening in the coming years to support 20,000 surgeries annually by 2031. The numbers are based on a $50,000 reimbursement estimate per surgery. Musk is banking on regulatory approval for Telepathy in the U.S. by 2029, which…
What's Your Reaction?
